APA

Gordon M. S., Matei D., Aghajanian C., Matulonis U. A., Brewer M., Fleming G. F., Hainsworth J. D., Garcia A. A., Pegram M. D., Schilder R. J., Cohn D. E., Roman L., Derynck M. K., Ng K., Lyons B., Allison D. E., Eberhard D. A., Pham T. Q., Dere R. C. & Karlan B. Y. (20060926). Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chicago

Gordon Michael S, Matei Daniela, Aghajanian Carol, Matulonis Ursula A, Brewer Molly, Fleming Gini F, Hainsworth John D, Garcia Agustin A, Pegram Mark D, Schilder Russell J, Cohn David E, Roman Lynda, Derynck Mika K, Ng Kimmie, Lyons Benjamin, Allison David E, Eberhard David A, Pham Thinh Q, Dere Randall C and Karlan Beth Y. 20060926. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Harvard

Gordon M. S., Matei D., Aghajanian C., Matulonis U. A., Brewer M., Fleming G. F., Hainsworth J. D., Garcia A. A., Pegram M. D., Schilder R. J., Cohn D. E., Roman L., Derynck M. K., Ng K., Lyons B., Allison D. E., Eberhard D. A., Pham T. Q., Dere R. C. and Karlan B. Y. (20060926). Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MLA

Gordon Michael S, Matei Daniela, Aghajanian Carol, Matulonis Ursula A, Brewer Molly, Fleming Gini F, Hainsworth John D, Garcia Agustin A, Pegram Mark D, Schilder Russell J, Cohn David E, Roman Lynda, Derynck Mika K, Ng Kimmie, Lyons Benjamin, Allison David E, Eberhard David A, Pham Thinh Q, Dere Randall C and Karlan Beth Y. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20060926.